Farmaceutica Remedia (BSE:RMAH) EV-to-EBIT : 6.26 (As of Jun. 24, 2024)

Farmaceutica Remedia EV-to-EBIT Chart

Farmaceutica Remedia Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
EV-to-EBIT		Get a 7-Day Free Trial					7.87	0.80	4.98	5.44	3.53

Farmaceutica Remedia Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															4.82	4.13	4.55	3.53	5.90

Competitive Comparison of Farmaceutica Remedia's EV-to-EBIT

For the Medical Distribution subindustry, Farmaceutica Remedia's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Farmaceutica Remedia's EV-to-EBIT Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Farmaceutica Remedia's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Farmaceutica Remedia's EV-to-EBIT falls into.

Farmaceutica Remedia EV-to-EBIT Calculation

Farmaceutica Remedia's EV-to-EBIT for today is calculated as:

Farmaceutica Remedia's current Enterprise Value is lei61.0 Mil.
Farmaceutica Remedia's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was lei9.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Farmaceutica Remedia  (BSE:RMAH) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Farmaceutica Remedia's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Farmaceutica Remedia's Enterprise Value for the quarter that ended in Mar. 2024 was lei57.6 Mil.
Farmaceutica Remedia's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was lei9.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Farmaceutica Remedia EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Farmaceutica Remedia's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Farmaceutica Remedia (BSE:RMAH) Business Description